Clinically the most relevant issues associated with chronic posttraumatic stress disorder appear as problems with self-regulation, including affect and impulse dysregulation; transient dissociative episodes; somatic complaints and altered relationships with self and others; as well as symptoms of depression and anxiety. Recommended medication for PTSD do not resolve all symptoms clusters, and can even worsen associated features. In searching for such medication which can stabilize mental tension, which improves information-processing and cognitive integration, that activates serotonergic pathways and improves sleep, we turned to risperidon (RispoleptR) due to its receptor profile.

The study was designed to establish the efficacy of risperidone in the treatment of associated symptoms in chronic posttraumatic stress disorder. Subjects with chronic PTSD were assessed during first visit and again at the end of the treatment, using the following instruments: MADRS, HAMA, MMPI and PIE. The results obtained show significant reduction in total MADRS and HAMA scores. The results of the psychological testing shed some light on the possible mechanism of action of this medicament. We discuss the results, our own clinical impressions and further directions in this area of importance as to develope more efficious and successful approach in the treatment of chronic PTSD.